HCPLive Network

Two-Way Tie for Hypoglycemia, Dementia in Diabetes

TUESDAY, June 11 (HealthDay News) -- For older adults with diabetes mellitus there appears to be a bidirectional correlation between hypoglycemia and dementia, according to research published online June 10 in JAMA Internal Medicine.

Kristine Yaffe, MD, from the University of California in San Francisco, and colleagues prospectively assessed the correlation between hypoglycemia and dementia in a biracial cohort including 783 older adults with diabetes mellitus (mean age, 74.0 years).

During a 12-year follow-up period, the researchers found that 7.8 percent of participants experienced a hypoglycemic event and 18.9 percent developed dementia. The risk of dementia was increased significantly for those who experienced versus those who did not experience a hypoglycemic event (34.4 versus 17.6 percent; multivariate-adjusted hazard ratio, 2.1). Compared with participants who did not develop dementia, those who developed dementia had a significantly greater risk of having a subsequent hypoglycemic event (14.2 versus 6.3 percent; multivariate-adjusted hazard ratio, 3.1). Similar results were seen after further adjustment for stroke, hypertension, myocardial infarction, and cognitive change scores.

"In summary, our results provide evidence for a bidirectional association between severe hypoglycemia and dementia," the authors write. "Hypoglycemia may impair cognitive health, and reduced cognitive function may increase the risk for a hypoglycemic event that could further compromise cognition, resulting in a detrimental cycle."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Patients with type 2 diabetes mellitus (T2DM) who initiate treatment with metformin have a lower risk of developing dementia.
For older adults with and without diabetes, higher glucose levels are associated with an increased risk of dementia.
Individuals with diabetes have a significantly higher risk of developing Alzheimer’s disease and other forms of dementia, a new study finds.
Examining evidence from epidemiologic, clinical, and animal studies, a team of researchers discussed the connection between neural dysfunction and metabolic disorders related to type 2 diabetes in the February 2014 issue of Current Diabetes Reports.
For patients with dementia, the rate of cognitive decline is slowed for those taking centrally acting angiotensin-converting-enzyme (ACE) inhibitors (CACE-Is), especially in the first six months of treatment.
For older adults, antihypertensive medications are associated with a decreased risk of Alzheimer's disease (AD) dementia.
In a recent clinical trial, Celexa (citalopram) reduced agitation in patients with probable Alzheimer’s disease (AD) compared to placebo, but the drug also produced severe cognitive and cardiac adverse events that prescribers must consider.
More Reading